HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in ISI Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via ISI Web of Science (7) Citing Articles via Google Scholar Google Scholar Articles by Peracchi, M Articles by Conte, D Search for Related Content PubMed PubMed Citation Articles by Peracchi, M Articles by Conte, D

Plasma chromogranin A in patients with autoimmune chronic atrophic gastritis, enterochromaffin-like cell lesions and gastric carcinoids

Gastroenterology Unit, Department of Medical Sciences, University of Milan, Ospedale Maggiore IRCCS, Milan, Italy

(Correspondence should be addressed to M Peracchi, Department of Medical Sciences, Ospedale Maggiore IRCCS, Padiglione Granelli, Via F Sforza 35, 20122 Milan, Italy; Email: maddalena.peracchi{at}unimi.it)

Objective: In atrophic body gastritis (ABG) chronic hypergastrinaemia stimulates enterochromaffin-like (ECL) cell proliferation with development of cell hyperplasia, dysplasia and possibly type-1 gastric carcinoids. As circulating chromogranin A (CgA) levels are a marker of neuroendocrine tumours, we evaluated the clinical usefulness of CgA assay in ABG patients to detect those with carcinoids.

Design and methods: Plasma CgA levels were measured using a commercial ELISA in 45 healthy volunteers, nine patients with type-1 gastric carcinoids and 43 consecutive ABG patients (21 without and 22 with ECL cell hyperplasia/dysplasia).

Results: CgA levels were significantly higher in ABG patients with and without gastric carcinoids than in healthy subjects (P < 0.001). The highest values occurred in patients with carcinoids (median (interquartile range): 58.1 (44.5–65.3) U/l) and with ECL cell hyperplasia/dysplasia (35.5 (31.8–48.65) U/l) but there were no significant differences in CgA among the various subgroups of ABG patients classified according to ECL cell status. Nevertheless, in ABG patients without carcinoids CgA values correlated with the presence and severity of ECL cell lesions (r_s = 0.428, P < 0.01). The sensitivity and specificity of the CgA assay in identifying patients with carcinoids were 100 and 23% respectively.

Conclusions: CgA plasma levels reflect the histological degree of ECL cell lesions in patients with ABG but the assay specificity is too low to detect among these patients those with gastric carcinoids.

This article has been cited by other articles:

				D Campana, F Nori, R Pezzilli, L Piscitelli, D Santini, E Brocchi, R Corinaldesi, and P Tomassetti Gastric endocrine tumors type I: treatment with long-acting somatostatin analogs Endocr. Relat. Cancer, March 1, 2008; 15(1): 337 - 342. [Abstract] [Full Text] [PDF]

				C. E. M. De Block, I. H. De Leeuw, and L. F. Van Gaal Autoimmune Gastritis in Type 1 Diabetes: A Clinically Oriented Review J. Clin. Endocrinol. Metab., February 1, 2008; 93(2): 363 - 371. [Abstract] [Full Text] [PDF]

				D. Campana, F. Nori, L. Piscitelli, A. M. Morselli-Labate, R. Pezzilli, R. Corinaldesi, and P. Tomassetti Chromogranin A: Is It a Useful Marker of Neuroendocrine Tumors? J. Clin. Oncol., May 20, 2007; 25(15): 1967 - 1973. [Abstract] [Full Text] [PDF]